We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    genetic biomarkers of executive stress
Previous Study | Return to List | Next Study

Genetic Biomarkers of Executive Stress

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02933203
First Posted: October 14, 2016
Last Update Posted: July 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Natalie Rasgon, Stanford University
  Purpose
The purpose of this study is to examine whether stress predicts telomere length in individuals who hold executive-level positions. Telomeres are the caps at the end of each strand of DNA that may affect how cells age. Subjects will complete an online survey/interview and provide one blood sample or saliva samples. The goal is to understand whether stress predicts genetic markers of longevity.

Condition
Stress

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Genetic Biomarkers of Executive Stress

Further study details as provided by Natalie Rasgon, Stanford University:

Primary Outcome Measures:
  • Telomere Length [ Time Frame: 1 day ]
    Subjects will come in for 1 visit to give a saliva or blood sample which will be used to measure telomere length.


Biospecimen Retention:   Samples With DNA
Saliva or blood samples

Enrollment: 51
Study Start Date: October 2015
Study Completion Date: June 2017
Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Detailed Description:

The primary aim of this study is to evaluate the relationship between overall levels of stress and telomere length. It is hypothesized that the high stress group (based on the Perceived Stress Scale)compared to low stress group will have shorter telomere length. A secondary aim is to evaluate whether different types of stress have differing degrees of association with telomere length. An exploratory aim is to assess for gender differences in the association between stress and telomere length. The investigators are collecting a number of other measures, including demographics, work sector, perceived social support, and medical history, in order to adjust for potential confounders in the analysis.

This study is an extension of earlier work Dr. Rasgon has done with Dr. Elizabeth Blackburn at UCSF on the relationship between telomere length and mood outcomes. The investigators hope this study will add to the growing body of literature on stress and genetic markers of longevity, specifically how stress level and type is associated with telomere length. The increased understanding gained through this study may provide leads for predicting age-related diseases and early mortality in adults, thus benefiting others in the future.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
100 subjects - individuals who hold executive-level positions. Participants are males and females, 18 or older, may be of any ethnic background. The investigators aim to recruit a diverse sample, reflective of the broader population.
Criteria

Inclusion Criteria:

  1. People of either gender >18 years of age.
  2. Subject hold executive-level position as defined as meeting the following criteria: having managerial responsibility over an organization or substantial part of an organization and/or having strategic influence over the direction of the organization
  3. Subject or representative is willing to sign the consent for prior to enrollment into the study, and to participate in all aspects of the study. Prospective subject must give verbal assent if unable to sign written consent.
  4. Adequate visual acuity to complete questionnaires.

Exclusion Criteria:

  1. Subjects will be excluded if they have any of the following medical conditions:

    1. active heart disease
    2. acute psychiatric disorder (hospitalized in the past year)
    3. any medical condition deemed exclusionary by the Principal Investigator (PI)
  2. Subject has a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within one year prior to screening.
  3. Subject is currently taking any medication deemed exclusionary by PI.
  4. Subject is pregnant, lactating, or planning to become pregnant during the study period.
  5. Subject is participating or has participated in another research study within 30 days prior to the screening visit.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02933203


Locations
United States, California
Stanford University
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Natalie Rasgon, M.D., Ph.D. Stanford University
  More Information

Responsible Party: Natalie Rasgon, Dr., Stanford University
ClinicalTrials.gov Identifier: NCT02933203     History of Changes
Other Study ID Numbers: 35668
First Submitted: October 12, 2016
First Posted: October 14, 2016
Last Update Posted: July 21, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No